open access

Vol 14, No 1 (2019)
Review Papers
Published online: 2019-04-10
Get Citation

Cardiovascular drug interactions with dietary components

Iwona Zieleń-Zynek, Joanna Kowalska, Agnieszka Będkowska-Szczepańska, Grzegorz Ziółkowski, Mariusz Gąsior, Bartosz Hudzik, Barbara Zubelewicz-Szkodzińska
DOI: 10.5603/FC.2019.0009
·
Folia Cardiologica 2019;14(1):46-51.

open access

Vol 14, No 1 (2019)
Review Papers
Published online: 2019-04-10

Abstract

The ageing society and the growing problem of fragility syndrome necessitate the long-term use of cardiac drugs, thereby increasing the risk from drug/food interactions. The aim of this study was to present the interaction between foods and those drugs used in the clinical practice of cardiologists. The effect of vitamin K antagonists is intensified by food and drink such as sage, camomile, parsley, aniseed, liquorice, ginger, ginseng, cranberry juice, and grapefruit juice, among others. However, products rich in vitamin K inhibit the therapeutic effect of coumarin derivatives. Due to the increased risk of bleeding, antiplatelet drugs should not be combined with dietary supplements containing Ginkgo biloba which inhibits platelet activating factor. The literature indicates the occurrence of a similar risk when combining antiplatelet drugs with garlic-containing supplements. Numerous scientific studies have looked at the impact of food on the absorption of antihypertensive drugs. The best known of these is grapefruit/grapefruit juice. It was recently found that grapefruit acts by interfering in the activity of cytochrome P450 3A4 (CYP3A4) enzyme. People who regularly take cardiac drugs are exposed to food/drug interactions, and should be aware of the possible complications. There is an urgent need to educate patients in the area of food/drug interactions. Therefore, a therapeutic team should be created consisting of a general practitioner, a cardiologist, a psychologist, a nurse and a dietician. 

Abstract

The ageing society and the growing problem of fragility syndrome necessitate the long-term use of cardiac drugs, thereby increasing the risk from drug/food interactions. The aim of this study was to present the interaction between foods and those drugs used in the clinical practice of cardiologists. The effect of vitamin K antagonists is intensified by food and drink such as sage, camomile, parsley, aniseed, liquorice, ginger, ginseng, cranberry juice, and grapefruit juice, among others. However, products rich in vitamin K inhibit the therapeutic effect of coumarin derivatives. Due to the increased risk of bleeding, antiplatelet drugs should not be combined with dietary supplements containing Ginkgo biloba which inhibits platelet activating factor. The literature indicates the occurrence of a similar risk when combining antiplatelet drugs with garlic-containing supplements. Numerous scientific studies have looked at the impact of food on the absorption of antihypertensive drugs. The best known of these is grapefruit/grapefruit juice. It was recently found that grapefruit acts by interfering in the activity of cytochrome P450 3A4 (CYP3A4) enzyme. People who regularly take cardiac drugs are exposed to food/drug interactions, and should be aware of the possible complications. There is an urgent need to educate patients in the area of food/drug interactions. Therefore, a therapeutic team should be created consisting of a general practitioner, a cardiologist, a psychologist, a nurse and a dietician. 

Get Citation

Keywords

interactions; cardiovascular drugs; dietary components

About this article
Title

Cardiovascular drug interactions with dietary components

Journal

Folia Cardiologica

Issue

Vol 14, No 1 (2019)

Pages

46-51

Published online

2019-04-10

DOI

10.5603/FC.2019.0009

Bibliographic record

Folia Cardiologica 2019;14(1):46-51.

Keywords

interactions
cardiovascular drugs
dietary components

Authors

Iwona Zieleń-Zynek
Joanna Kowalska
Agnieszka Będkowska-Szczepańska
Grzegorz Ziółkowski
Mariusz Gąsior
Bartosz Hudzik
Barbara Zubelewicz-Szkodzińska

References (34)
  1. Główny Urząd Statystyczny 2015. Zdrowie i zachowanie zdrowotne mieszkańców Polski w świetle Europejskiego Ankietowego Badania Zdrowia (EHIS). 2014; 1-12.
  2. Ksiądzyna D, Szeląg A. Specyfika farmakoterapii pacjentów w podeszłym wieku. Psychoger Pol. 2013; 10(3): 115–126.
  3. Swora-Cwynar E, Marcinkowska E, Olejniczak M. Interactions Between Food and Drugs. Nursing and Public Health. 2015; 5(4): 427–439.
  4. Woroń J. Błędy w leczeniu przeciwzakrzepowym – czyli 7 grzechów głównych stosowania leków przeciwzakrzepowych, przeciwpłytkowych oraz przeciwkrwotocznych w praktyce lekarskiej. Anest Ratow. 2017; 11: 211–221.
  5. Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 2017; 31(4): 193–203.
  6. Woźnicka-Leśkiewicz L, Wolska-Bułach A, Tykarski A. Interakcje antykoagulantów z lekami i żywnością – wskazówki dla lekarza praktyka. Chor Serca Naczyń. 2014; 11(2): 78–90.
  7. Ciborowska H, Rudnicka A. Dietetyka. Żywienie zdrowego i chorego człowieka. PZWL 2009: 149.
  8. Kim KH, Choi WS, Lee JH, et al. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost. 2010; 104(4): 755–759.
  9. Saito R, Takeda K, Yamamoto K, et al. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake. J Thromb Thrombolysis. 2014; 38(1): 105–114.
  10. Rosłonkiwicz K, Sjebert J. Wpływ czynników środowiskowych na działanie antykoagulantów doustnych. Forum Med Rodz. 2013; 7(4): 208–214.
  11. Kasprzak J, Dąbrowski R, Barylski M, et al. Doustne antykoagulanty nowej generacji — aspekty praktyczne. Stanowisko Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Folia Cardiologica. 2016; 11(5): 377–393.
  12. Mądra-Gackowska K, Gackowski M, et al. Siedlecka-Główczewska Możliwości terapeutyczne wykorzystania kwasu acetylosalicylowego w populacji pacjentów geriatrycznych. Gereontol Pol. 2017; 25: 212–215.
  13. Bąk-Romaniszyn L, Czkwianianc E, Cywińska-Bernas A. Choroby społeczne i cywilizacyjne – wybrane zagadnienia. , Łódź 2013: 65.
  14. Kowalczyk A, Błaszczyk F, Orłowska A, et al. Ryzyko wystąpienia interakcji pomiędzy lekami a preparatami pochodzenia roślinnego wśród pacjentów objętych opieką paliatywną i hospicyjną. Med Paliat. 2014; 6(3): 140–144.
  15. Lim JW, Chee SX, Wong WJ, et al. Traditional Chinese medicine: herb-drug interactions with aspirin. Singapore Med J. 2018; 59(5): 230–239.
  16. Gajewski P, Tomaniak M, Filipiak K. Paraoksonaza 1 – co o niej obecnie wiadomo? Folia Cardiol. 2015; 10(3): 183–189.
  17. Tykarski A, Widecka K, Narkiewicz K, et al. Leki złożone w terapii nadciśnienia tętniczego w Polsce. Stanowisko Ekspertów Polskiego Towarzystwa Nadciśnienia Tętniczego oraz Sekcji Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Arterial Hypertension. 2017; 21(3): 105–115.
  18. Mroczek A, Pawlicki M, Pawlicka M. Nadciśnienie tętnicze – epidemiologia i etiologia. In: Bednarski J. ed. Nauki Przyrodnicze i Medyczne: Żywienie, sport oraz zdrowie. Instytut Promocji Kultury i Nauki, Lublin 2018: 143–151.
  19. Woźnicka Le, Wolska-Bułach A, Posadzy-Małaczyńska A. Interakcje między lekami hipotensyjnymi i żywnością. Arterial Hypertens. 2011; 15(3): 201–209.
  20. Ramalingam K, Rajagopal SS, Kandasamy K, et al. et al.. A prospective study on potential drug interactions among hospitalized patients in the cardiology departments in tertiary care hospitals. Indian J Ap Res. 2018; 8(5): 65–68.
  21. Currie GM. Pharmacology, Part 2: Introduction to Pharmacokinetics. J Nucl Med Technol. 2018; 46(3): 221–230.
  22. Fugh-Berman A, Ernst E, Fugh-Berman A. Herb-drug interactions. Lancet. 2000; 355(9198): 134–138.
  23. Matławska I. Farmakognozja. UM Poznań, Poznań 2008: 256–274.
  24. Langer D, Stryczyński Ł, Szturo A, et al. Nadciśnienie tętnicze indukowane przez lukrecję. Nadciśnienie Tętnicze. 2014; 18(3): 121–126.
  25. Pirmohamed M. Drug-grapefruit juice interactions: two mechanisms are clear but individual responses vary. BMJ. 2013; 346: f1.
  26. Bailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ. 2013; 185(4): 309–316.
  27. Spencer EA, Key TJ, Appleby PN, et al. Prospective study of the association between grapefruit intake and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control. 2009; 20(6): 803–809.
  28. Holmberg MT, Tornio A, Neuvonen M, et al. Grapefruit juice inhibits the metabolic activation of clopidogrel. Clin Pharmacol Ther. 2014; 95(3): 307–313.
  29. Bartmańska M, Adamczak M, Więcek A. Selected food products that may cause increase of blood pressure. Nadciśnienie tętnicze. 2013; 17(5): 384–392.
  30. Zachwieja Z. Interakcje leków z pożywieniem. Medpharm, Wrocław 2008: 195–247.
  31. Milešević J, Samaniego L, Kiely M, et al. Specialized food composition dataset for vitamin D content in foods based on European standards: Application to dietary intake assessment. Food Chem. 2018; 240: 544–549.
  32. Saran-Jagodzińska A, Wytlib A. Ocena wiedzy osób starszych z powiatu konińskiego na temat interakcji leków z żywnością. Geriatr. 2018; 12: 19–28.
  33. Suliburska J, Bogdański P, et al. Chiniewicz Ocena sposobu żywienia i stanu odżywienia pacjentów z pierwotnym nadciśnieniem tętniczym w aspekcie stosowanej farmakoterapii. Farmacja Współczesna. 2010; 3: 5–10.
  34. Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM. 2012; 105(5): 487–491.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl